Influence of preformed alpha-helix and alpha-helix induction on the activity of cationic antimicrobial peptides.
One prominent class of cationic antibacterial peptides comprises the alpha-helical class, which is unstructured in free solution but folds into an amphipathic alpha-helix upon insertion into the membranes of target cells. To investigate the importance of alpha-helicity and its induction on interaction with membranes, a series of peptides was constructed based on a hybrid of moth cecropin (amino acids 1-8) and bee melittin (amino acids 1-18) peptides. The new peptides were predicted to have a high tendency to form alpha-helices or to have preformed alpha-helices by virtue of construction of a lactam bridge between glutamate and lysine side-chains at positions i and i + 4 at various locations along the primary sequence. In two examples where the use of lactam bridge constraints induced and stabilized alpha-helical structure in benign (aqueous buffer) and/or hydrophobic medium, there was a decrease in antibacterial activity relative to the linear counterparts. Thus the preformation of alpha-helix in solution was not necessarily beneficial to antimicrobial activity. In the one case where the lactam bridge did result in increased antibacterial activity (lower minimal inhibitory concentration values) it did not increase alpha-helical content in benign or hydrophobic medium. Broadly speaking, good activity of the peptides against Pseudomonas aeruginosa correlated best (r2 = 0.88) with a helican parameter which was calculated as the induction of alpha-helix in a membrane-mimicking environment divided by the alpha-helix formation under benign conditions. Interestingly, the activity of the lactam bridge peptide constructs correlated in part with alterations in bacterial outer or cytoplasmic membrane permeability.
Houston
M E
ME
Protein Engineering Network of Centres of Excellence, University of Alberta, Edmonton, Canada.
Kondejewski
L H
LH
Karunaratne
D N
DN
Gough
M
M
Fidai
S
S
Hodges
R S
RS
Hancock
R E
RE
D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides; D002176:Candida albicans / Q000187:drug effects; D002352:Carrier Proteins / Q000737:chemistry / Q000494:pharmacology; D002463:Cell Membrane Permeability; D002942:Circular Dichroism; D004926:Escherichia coli / Q000187:drug effects; D019476:Insect Proteins / Q000737:chemistry / Q000494:pharmacology; D007769:Lactams / Q000737:chemistry / Q000494:pharmacology; D008555:Melitten / Q000737:chemistry / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry* / Q000494:pharmacology*; D017510:Protein Folding; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011994:Recombinant Proteins / Q000737:chemistry / Q000494:pharmacology; D013212:Staphylococcus epidermidis / Q000187:drug effects; D013329:Structure-Activity Relationship
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D002352:Carrier Proteins; D019476:Insect Proteins; D007769:Lactams; C102568:MBI-27 protein, recombinant; D010455:Peptides; D011994:Recombinant Proteins; D008555:Melitten